Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity

5-Fluorouracil (5-FU) remains to be the backbone of chemotherapy regimens approved for treatment of colorectal cancer and other gastrointestinal cancers and breast cancer. The incidence of cardiotoxicity associated with 5-FU ranges from 1.5–18%. Previous studies also concluded that rechallenging a p...

Descripción completa

Detalles Bibliográficos
Autor principal: Saif, Muhammad Wasif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553662/
https://www.ncbi.nlm.nih.gov/pubmed/33116601
http://dx.doi.org/10.2147/OTT.S264156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553662/
https://www.ncbi.nlm.nih.gov/pubmed/33116601
http://dx.doi.org/10.2147/OTT.S264156

Ejemplares similares